<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792570</url>
  </required_header>
  <id_info>
    <org_study_id>HLS03/2012</org_study_id>
    <nct_id>NCT01792570</nct_id>
  </id_info>
  <brief_title>DRV/r + RPV QD: Efficacy and Toxicity Reduction</brief_title>
  <official_title>Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASST Fatebenefratelli Sacco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elisa Colella, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Valentina Di Cristo, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massimo Galli, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ASST Fatebenefratelli Sacco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical approach to HIV infection treatment is based on the use of highly active
      antiretroviral therapies (HAART) and recent national and international guidelines for guiding
      HIV therapy recommend the use of triple-combination therapy using antiretrovirals with 2
      nucleos(t)ide inhibitors [N(n)RTI] as backbone plus a third drug to be chosen among a boosted
      protease inhibitor (PI/r), a nonnucleoside inhibitor (NNRTI) or an integrase inhibitor (II).

      In spite of evident efficacy of HAART, as demonstrated by survival increasing, long term side
      effects, as for example the impact on renal function, remain principal problem.

      In patient with risk factor for renal disease, a reduction of eGRF (estimated Glomerular
      Filtration Rate) between 90 and 60 mL/min/1,73 m2 could be already considered as a risk
      condition [1,2].

      Efficacy of HAART, with increase of media survival and the parallel decrease of mortality,
      has underlined the necessity to reflect on long term HAART effects [3].

      There are many evidences of HAART-related toxicity that, in spite of the necessity of a
      life-saving therapy, focus on the additional costs of this situation, in terms of health as
      well as in terms of economic costs.

      Particular attention has been focused on the impact of some drugs on renal function, as
      tenofovir, especially on tubule, without forgetting the modification of lipid and bone
      metabolisms.

      According to further studies which have evidenced the potential of some recently introduced
      molecules [4,5], the investigators had the need to realize a study to deepen the feasibility
      of a dual-therapy that permit to exclude NRTIs from the backbone, with the aim to prevent
      NRTIs-related long-term toxicity.

      The investigators have designed a prospective randomized controlled trial, open-label, with a
      duration of 96 weeks, to compare the efficacy of a dual-therapy based on rilpivirine 25mg
      plus darunavir 800mg/ritonavir 100mg QD, in HIV-positive subjects with suppressed viremia
      from at least 3 months. In fact, there are a few data about association of these drugs, which
      it has been shown to be safe, well tolerated, and with a strong pharmacological synergy,
      without nucleos(t)idic backbone, while the necessity to minimize the costs toxicity-related
      is becoming increasingly compelling.

      According to clinical experience and literature data, the investigators hope this study shows
      positive results in term of immune-virological efficacy, as well as in term of decrease of
      VACS index - a complex parameter which has the purpose to quantify general organic decay -
      and markers of lipid and bone metabolism, in group which receives dual-therapy versus the
      group with standard therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot, phase III prospective, randomized, open-label, multicentric controlled study, which
      will offer a novel dual-therapy regimen including RPV 25mg + DRV 800mg/rtv 100mg QD to HIV+
      subjects with suppressed viremia.

      132 HIV+ subjects will be randomized, 1:1, to switch to RPV+DRV/r versus continue triple-drug
      therapy. Subjects will be switched from any PI/r-containing regimen.

      The duration of the study is 96 weeks and patients will be stratified according to their HCV
      serostatus (Ab positive or negative), age (&gt; or &lt; 50 years), and immunological status
      (CD4&lt;200/µL; CD4=200-500/µL; CD4&gt;500/µL). It is planned to enroll at least 30% of female
      subjects.

      Follow-up visits will be performed at 4, 8, 12, 24, 36, 48, 60, 72, and 96 weeks (laboratory
      and physical examination).

      Effectiveness will be measured by determination of HIV-RNA, safety will be evaluated by
      determination of AST, ALT, creatinine, plasmatic and urinary phosphate, albuminuria, total
      cholesterol, HDL and LDL cholesterol, triglycerides at the follow-up visits.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-RNA &lt; 50 cp/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Responders: HIV+ subjects with HIV-RNA &lt; 50 cp/mL at week 48 according to the intention-to-treat (ITT-TLOVR) approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACTG grade III and IV events.</measure>
    <time_frame>over 96 weeks.</time_frame>
    <description>Safety will be assessed through the number of ACTG grade III and IV in the specified safety parameters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>RPV + DRV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switch to RPV + DRV/r</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continue the PI/r-containing HAART.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continue the PI/r-containing HAART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPV + DRV/r</intervention_name>
    <description>Switch to dual HAART</description>
    <arm_group_label>RPV + DRV/r</arm_group_label>
    <other_name>RVP: rilpivirine; brand name: EdurantTM.</other_name>
    <other_name>DRV: darunavir; brand name: PrezistaTM.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continue the PI/r-containing HAART.</intervention_name>
    <description>Continue the on-going triple drug HAART.</description>
    <arm_group_label>continue the PI/r-containing HAART.</arm_group_label>
    <other_name>the drugs will depend on the successful regimen.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult HIV+ subjects (&gt;18 years old), giving and signing an informed consent;

          -  Any HAART treatment for at least 12 months;

          -  Current treatment with a PI/r-containing regimen initiated at least 6 months earlier;

          -  HIV-RNA &lt;50 cp/mL for at least 3 months, without viral blip due to virologic failure
             at any time;

          -  Any nadir CD4 lymphocytes;

          -  Current CD4 count &gt; 100 cell/uL;

          -  eGFRs &gt;60 mL/min/1.73 m2.

        Exclusion Criteria:

          -  Previous drug resistance genotypic test showing the presence of any RPV (RT: K101E/P,
             E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C, M230I/L) or DRV (protease: V11I,
             V32I, L33F, I47V, I50V, I54M/L, T74P, L76V, I84V, L89V) resistance associated mutation
             (RAM), according to the November 2011 IAS-USA list;

          -  Child-Pugh C or grade 3-4 AST or ALT values;

          -  Acute cardiovascular event within 6 months;

          -  AIDS event within 6 months;

          -  Current IVDU;

          -  HBsAg +;

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano - Rusconi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DIBIC &quot;Luigi Sacco&quot;, Università degli Studi di Milano, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano - Rusconi, M.D.</last_name>
    <phone>0039 02 39042949</phone>
    <email>stefano.rusconi@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Policlinico Universitario</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gioacchino Angarano, M.D.</last_name>
      <email>g.angarano@clininf.uniba.it</email>
    </contact>
    <investigator>
      <last_name>Gioacchino Angarano, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Malattie Infettive, Ospedale S. Maria Annunziata, Antella</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Lo Caputo, M.D.</last_name>
      <email>sergio.locaputo@asf.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Lo Caputo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Ospedale San Martino, Università degli Studi</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Di Biagio, M.D.</last_name>
      <email>antonio.dibiagio@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Di Biagio, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Malattie Infettive, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Gori, M.D.</last_name>
      <email>andrea.gori@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Gori, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Clinicizzata di Malattie Infettive dell'Università degli Studi, Dipartimento di Scienze Biomediche e Cliniche &quot;Luigi Sacco&quot;</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Rusconi, M.D.</last_name>
      <email>stefano.rusconi@unimi.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisa Colella, M.D.</last_name>
      <email>elisa_colella@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Stefano Rusconi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I e II Divisione Malattie Infettive, Azienda Ospedaliera-Polo Universitario &quot;Luigi Sacco&quot;</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliano Rizzardini, M.D.</last_name>
      <email>rizzardini.giuliano@hsacco.it</email>
    </contact>
    <investigator>
      <last_name>Giuliano Rizzardini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Malattie Infettive, Policlinico Universitario</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Mussini, M.D.</last_name>
      <email>crimuss@unimore.it</email>
    </contact>
    <investigator>
      <last_name>Cristina Mussini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Malattie Infettive, Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Maserati, M.D.</last_name>
      <email>rmaserati@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Renato Maserati, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Policlinico &quot;Tor Vergata&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Andreoni, M.D.</last_name>
      <email>andreoni@uniroma2.it</email>
    </contact>
    <contact_backup>
      <last_name>Loredana Sarmati, M.D.</last_name>
      <email>sarmati@med.uniroma2.it</email>
    </contact_backup>
    <investigator>
      <last_name>Massimo Andreoni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Di Giambenedetto, M.D.</last_name>
      <email>simona.digiambenedetto@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Simona Di Giambenedetto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Malattie Infettive, Azienda Policlinico Umberto I, Università degli Studi &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Vullo, M.D.</last_name>
      <email>vincenzo.vullo@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Gabriella D'Ettorre, M.D.</last_name>
      <email>gabriella.dettorre@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Vincenzo Vullo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Ospedale Amedeo di Savoia, Università degli Studi</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Bonora, M.D.</last_name>
      <email>stefano.bonora@unito.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Bonora, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Maggi P, Bartolozzi D, Bonfanti P, Calza L, Cherubini C, Di Biagio A, Marcotullio S, Montella F, Montinaro V, Mussini C, Narciso P, Rusconi S, Vescini F. Renal complications in HIV disease: between present and future. AIDS Rev. 2012 Jan-Mar;14(1):37-53. Review.</citation>
    <PMID>22297503</PMID>
  </reference>
  <reference>
    <citation>Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012 Jun 5;156(11):785-95, W-270, W-271, W-272, W-273, W-274, W-275, W-276, W-277, W-278. doi: 10.7326/0003-4819-156-6-201203200-00391. Epub 2012 Feb 6. Review.</citation>
    <PMID>22312131</PMID>
  </reference>
  <reference>
    <citation>Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010 Jan;85(1):1-18. doi: 10.1016/j.antiviral.2009.10.002. Epub 2009 Dec 16. Review.</citation>
    <PMID>20018391</PMID>
  </reference>
  <reference>
    <citation>Burgos J, Crespo M, Falcó V, Curran A, Imaz A, Domingo P, Podzamczer D, Mateo MG, Van den Eynde E, Villar S, Ribera E. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. J Antimicrob Chemother. 2012 Jun;67(6):1453-8. doi: 10.1093/jac/dks057. Epub 2012 Feb 29.</citation>
    <PMID>22378681</PMID>
  </reference>
  <reference>
    <citation>Clumeck N, Cahn P, Molina JM, Mills A, Nijs S, Vingerhoets J, Witek J. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials. Int J STD AIDS. 2010 Nov;21(11):738-40. doi: 10.1258/ijsa.2010.010139.</citation>
    <PMID>21187353</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ASST Fatebenefratelli Sacco</investigator_affiliation>
    <investigator_full_name>Stefano Rusconi</investigator_full_name>
    <investigator_title>Associate professor in infectious diseases</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>darunavir</keyword>
  <keyword>rilpivirine</keyword>
  <keyword>strategic study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

